Showing results (111-120 of 124) with videos related to
Sort By:
Pageof 13
United European Gastroenterology Journal|December 24, 2025
Integrated Multi-Omic Analysis Identifies Altered Colonic Brush Border Profile as a Key Feature of Microscopic ColitisDanila Guagnozzi, Ana Maria Gonzalez-Castro, Yamile Zabana, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.Breast Cancer Research : BCR|July 12, 2014
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerPatrick C O'Leary, Marta Terrile, Malgorzata Bajor, et al.Cancer Research|August 5, 2008
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerKatherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, et al.Plos One|September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.Pageof 13